Callan Family Office LLC Takes Position in DexCom, Inc. (NASDAQ:DXCM)

Callan Family Office LLC purchased a new stake in DexCom, Inc. (NASDAQ:DXCM) in the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund purchased 3,061 shares of the medical device company’s stock, valued at approximately $238,000.

A number of other hedge funds and other institutional investors have also bought and sold shares of DXCM. Van ECK Associates Corp increased its stake in shares of DexCom by 14.0% in the third quarter. Van ECK Associates Corp now owns 20,191 shares of the medical device company’s stock valued at $1,463,000 after buying an additional 2,475 shares during the period. CWA Asset Management Group LLC bought a new stake in DexCom in the third quarter valued at approximately $222,000. Covestor Ltd boosted its holdings in shares of DexCom by 53.7% during the 3rd quarter. Covestor Ltd now owns 959 shares of the medical device company’s stock worth $64,000 after buying an additional 335 shares in the last quarter. Crossmark Global Holdings Inc. boosted its holdings in shares of DexCom by 1.0% during the 3rd quarter. Crossmark Global Holdings Inc. now owns 18,778 shares of the medical device company’s stock worth $1,259,000 after buying an additional 182 shares in the last quarter. Finally, Catalytic Wealth RIA LLC boosted its holdings in shares of DexCom by 22.0% during the 3rd quarter. Catalytic Wealth RIA LLC now owns 2,984 shares of the medical device company’s stock worth $200,000 after buying an additional 538 shares in the last quarter. Institutional investors and hedge funds own 97.75% of the company’s stock.

Insiders Place Their Bets

In other DexCom news, EVP Jereme M. Sylvain sold 7,000 shares of the firm’s stock in a transaction dated Monday, March 10th. The stock was sold at an average price of $73.83, for a total value of $516,810.00. Following the completion of the transaction, the executive vice president now owns 135,482 shares in the company, valued at $10,002,636.06. This trade represents a 4.91 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, CEO Kevin R. Sayer sold 33,359 shares of the firm’s stock in a transaction dated Wednesday, January 29th. The stock was sold at an average price of $86.91, for a total value of $2,899,230.69. Following the completion of the transaction, the chief executive officer now owns 319,037 shares of the company’s stock, valued at approximately $27,727,505.67. This represents a 9.47 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 45,083 shares of company stock worth $3,826,604 in the last quarter. 0.30% of the stock is owned by company insiders.

DexCom Stock Down 0.7 %

DXCM stock opened at $70.26 on Wednesday. The company has a debt-to-equity ratio of 0.59, a quick ratio of 1.28 and a current ratio of 1.47. The company has a market capitalization of $27.46 billion, a price-to-earnings ratio of 49.13, a PEG ratio of 2.30 and a beta of 1.28. DexCom, Inc. has a fifty-two week low of $62.34 and a fifty-two week high of $142.00. The stock has a fifty day moving average of $84.53 and a 200-day moving average of $76.98.

DexCom (NASDAQ:DXCM) last posted its quarterly earnings results on Thursday, February 13th. The medical device company reported $0.45 earnings per share for the quarter, missing the consensus estimate of $0.50 by ($0.05). DexCom had a return on equity of 30.14% and a net margin of 14.29%. As a group, equities research analysts predict that DexCom, Inc. will post 2.03 earnings per share for the current year.

Analysts Set New Price Targets

A number of equities analysts have issued reports on DXCM shares. Robert W. Baird upgraded DexCom from a “neutral” rating to an “outperform” rating and increased their price target for the stock from $86.00 to $104.00 in a report on Thursday, January 16th. Redburn Atlantic raised DexCom from a “neutral” rating to a “buy” rating and upped their target price for the stock from $85.00 to $115.00 in a research report on Monday, February 3rd. Morgan Stanley upped their target price on DexCom from $75.00 to $82.00 and gave the stock an “equal weight” rating in a research report on Friday, February 14th. Wells Fargo & Company reaffirmed an “overweight” rating on shares of DexCom in a research report on Saturday. Finally, Canaccord Genuity Group upped their target price on DexCom from $99.00 to $103.00 and gave the stock a “buy” rating in a research report on Friday, February 14th. Four equities research analysts have rated the stock with a hold rating, thirteen have assigned a buy rating and two have given a strong buy rating to the company’s stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $99.82.

DexCom Company Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.